(Total Views: 415)
Posted On: 08/28/2020 11:49:49 AM
Post# of 653
Thank you - all for posting - good to keep this limited to pertinent documentation.
Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide
Jonathan Javitt * and Jihad Youssef
Version 1 : Received: 27 August 2020 / Approved: 28 August 2020 / Online: 28 August 2020 (11:38:23 CEST)
https://www.preprints.org/manuscript/202008.0640/v1
Comment: The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.
Hospital course and adverse events. The time to ICU discharge ranged from 1 – 14 days in the 4 of 6 patients so far
discharged from intensive care (Table 2).
Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide
Jonathan Javitt * and Jihad Youssef
Version 1 : Received: 27 August 2020 / Approved: 28 August 2020 / Online: 28 August 2020 (11:38:23 CEST)
https://www.preprints.org/manuscript/202008.0640/v1
Comment: The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.
Hospital course and adverse events. The time to ICU discharge ranged from 1 – 14 days in the 4 of 6 patients so far
discharged from intensive care (Table 2).
(1)
(0)
